Gynecologic Oncology Reports最新文献

筛选
英文 中文
Stage I placental site trophoblastic tumor with complete response after pembrolizumab 派姆单抗治疗后完全缓解的I期胎盘部位滋养细胞肿瘤
IF 1.3
Gynecologic Oncology Reports Pub Date : 2026-02-01 Epub Date: 2026-01-05 DOI: 10.1016/j.gore.2026.102023
Pierre Descargues , Lua R. Eiriksson , Pascal Rousset , Adrien Msika , Benoit You , Alexis Trecourt , Jerome Massardier , Touria Hajri , Bruno Borghese , François Golfier , Pierre-Adrien Bolze , Jérôme Alexandre
{"title":"Stage I placental site trophoblastic tumor with complete response after pembrolizumab","authors":"Pierre Descargues , Lua R. Eiriksson , Pascal Rousset , Adrien Msika , Benoit You , Alexis Trecourt , Jerome Massardier , Touria Hajri , Bruno Borghese , François Golfier , Pierre-Adrien Bolze , Jérôme Alexandre","doi":"10.1016/j.gore.2026.102023","DOIUrl":"10.1016/j.gore.2026.102023","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102023"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary lymphatic leiomyosarcoma presenting as a pelvic mass 原发性淋巴平滑肌肉瘤表现为盆腔肿块
IF 1.3
Gynecologic Oncology Reports Pub Date : 2026-02-01 Epub Date: 2026-01-19 DOI: 10.1016/j.gore.2026.102037
Bridget S. Dillon , Rayan M. Sibira , Laura Miller , Morgan Gruner , Mahmoud Khalifa , Britt K. Erickson
{"title":"Primary lymphatic leiomyosarcoma presenting as a pelvic mass","authors":"Bridget S. Dillon ,&nbsp;Rayan M. Sibira ,&nbsp;Laura Miller ,&nbsp;Morgan Gruner ,&nbsp;Mahmoud Khalifa ,&nbsp;Britt K. Erickson","doi":"10.1016/j.gore.2026.102037","DOIUrl":"10.1016/j.gore.2026.102037","url":null,"abstract":"<div><h3>Introduction</h3><div>Leiomyosarcoma (LMS) most commonly presents in the uterus or as a primary retroperitoneal mass. LMS metastases to the lymph nodes is exceedingly rare and to our knowledge there are no reported cases of lymphatic confined LMS.</div><div>Case Presentation.</div><div>A 72-year-old woman presented with intermittent lower abdominal cramping for about one year. Her surgical history was notable for a total abdominal hysterectomy (TAH) and bilateral salpingo-oophorectomy (BSO) for uterine fibroids, 25 years prior to presentation. She had no other notable medical history. She was found to have a 9 cm complex pelvic mass, extensive bulky pelvic and retroperitoneal lymphadenopathy and an enlarged right supraclavicular lymph node. Biopsies of the right supraclavicular lymph nodes, right <em>para</em>-aortic lymph nodes, and complex pelvic mass showed benign leiomyomatosis. Surgical debulking was performed including pelvic mass resection, and extensive lymphadenectomy. Final pathology confirmed metastatic LMS. The pelvic mass was found to be an enlarged obturator lymph node, positive for LMS. All visible disease was resected. She was started on an aromatase inhibitor postoperatively and has been disease free for 16 months.</div></div><div><h3>Conclusion</h3><div>This is a unique case of widely metastatic, yet lymphatic confined LMS in a patient with very remote history of TAH/BSO. The tumor responded well to surgical resection and aromatase inhibition. Although traditionally LMS does not involve lymphatic spread, this case demonstrates that LMS should remain in the differential when bulky lymphadenopathy is encountered. While there are rare cases of primary retroperitoneal LMS, this may be the first reported case of primary lymphatic LMS.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102037"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severe leukemoid reaction and spontaneous tumor lysis syndrome in a young patient with undifferentiated Lynch syndrome-associated ovarian cancer 未分化Lynch综合征相关性卵巢癌年轻患者的严重类白血病反应和自发肿瘤溶解综合征
IF 1.3
Gynecologic Oncology Reports Pub Date : 2026-02-01 Epub Date: 2026-01-07 DOI: 10.1016/j.gore.2026.102026
Claudia Marie S. Watkins , Mojtaba Allahifard , Juan Cattoni , Lauren Montemorano
{"title":"Severe leukemoid reaction and spontaneous tumor lysis syndrome in a young patient with undifferentiated Lynch syndrome-associated ovarian cancer","authors":"Claudia Marie S. Watkins ,&nbsp;Mojtaba Allahifard ,&nbsp;Juan Cattoni ,&nbsp;Lauren Montemorano","doi":"10.1016/j.gore.2026.102026","DOIUrl":"10.1016/j.gore.2026.102026","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102026"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145920936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early-stage sertoliform endometrioid carcinoma of the ovary: diagnostic, molecular, and therapeutic considerations 卵巢早期浆状子宫内膜样癌:诊断、分子和治疗考虑
IF 1.3
Gynecologic Oncology Reports Pub Date : 2026-02-01 Epub Date: 2026-01-08 DOI: 10.1016/j.gore.2026.102025
Janhvi Sookram , Nisha Garg , Kevin B. Gilchrist
{"title":"Early-stage sertoliform endometrioid carcinoma of the ovary: diagnostic, molecular, and therapeutic considerations","authors":"Janhvi Sookram ,&nbsp;Nisha Garg ,&nbsp;Kevin B. Gilchrist","doi":"10.1016/j.gore.2026.102025","DOIUrl":"10.1016/j.gore.2026.102025","url":null,"abstract":"<div><h3>Background</h3><div>The sertoliform variant of ovarian endometrioid carcinoma is exceedingly rare and often mimics sex-cord stromal or Brenner tumors, creating diagnostic challenges. <strong>Case</strong><strong>:</strong> A 72-year-old woman presented with progressive abdominal distention and pain. MRI revealed a 22.7 × 13.8 × 16 cm mixed cystic–solid pelvic mass with mild ascites and elevated tumor markers. She underwent total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and lymphadenectomy. Pathology demonstrated low-grade endometrioid carcinoma, sertoliform variant, confined to the left ovary. Immunostains were positive for ER, AE1/AE3, β-catenin (nuclear/cytoplasmic), CDX2, and EMA. Molecular profiling revealed CTNNB1 (p.S33A) and FBXW7 (p.Q624*) pathogenic variants. She received adjuvant letrozole and remains disease-free at 3 years post-surgery. <strong>Conclusion</strong><strong>:</strong> This case highlights the diagnostic complexity of ovarian tumors with sertoliform morphology and the importance of integrating morphologic, immunohistochemical, and molecular data. When confined to the ovary, prognosis is excellent following surgical resection. Endocrine therapy may be considered on an individualized basis in hormone-responsive tumors, although its role in early-stage disease remains unproven.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102025"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vulvar dermatofibrosarcoma protuberans in a 55-year-old female: A case report, surgical reconstruction approach and literature review 55岁女性外阴隆突性皮肤纤维肉瘤1例报告、手术重建方法及文献复习
IF 1.3
Gynecologic Oncology Reports Pub Date : 2026-02-01 Epub Date: 2026-01-06 DOI: 10.1016/j.gore.2026.102024
Amanda Detrés , Itzamar Pastrana , Marjolaine Suárez , Ricardo Gómez
{"title":"Vulvar dermatofibrosarcoma protuberans in a 55-year-old female: A case report, surgical reconstruction approach and literature review","authors":"Amanda Detrés ,&nbsp;Itzamar Pastrana ,&nbsp;Marjolaine Suárez ,&nbsp;Ricardo Gómez","doi":"10.1016/j.gore.2026.102024","DOIUrl":"10.1016/j.gore.2026.102024","url":null,"abstract":"<div><h3>Background</h3><div>Dermatofibrosarcoma protuberans (DFSP) is a rare, locally aggressive soft tissue sarcoma characterized by a high risk of local recurrence. Vulvar involvement is exceedingly uncommon and often misdiagnosed as a bening lesion, resulting in delayed diagnosis. Complete surgical excision with negative margins is essential but can be challenging in anatomically sensitive areas as the vulva.</div></div><div><h3>Case presentation</h3><div>A 55-year-old Puerto Rican woman presented with a slowly enlarging lesion of the left labia majora that was initially managed as a furuncle. Progressive growth and symptoms prompted biopsy, which confirmed DFSP. Staging imaging revealed no metastatic disease. The patient underwent a single-stage left radical hemivulvectomy with immedate reconstruction using a V-Y fasciocutaneous advancement flap. Histopathologic examination demonstrated classic DFSP with uniform spindle cellls in a storiform pattern, stong diffuse CD34 positivity, and negative surgical margins. Postoperative recovery was uncomplicated, with excellent wound healing and flap viability.</div></div><div><h3>Conclusion</h3><div>This case emphasizes the importance of early biopsy of persistent vulvar lesions and highlights the role of multidiciplinary surgical planning. Single-stage radical excision with immediate reconstruction can achieve favorable oncologic and functional outcomes in vulvar DFSP. Long-term surveillance remains essential due to the potential for late local recurrence.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102024"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term remission after multimodal therapy in metastatic small cell carcinoma of the ovary, hypercalcemic type: A case report 卵巢转移性小细胞癌多模式治疗后的长期缓解,高钙血症型:1例报告
IF 1.3
Gynecologic Oncology Reports Pub Date : 2026-02-01 Epub Date: 2025-12-29 DOI: 10.1016/j.gore.2025.102020
Elora Castanet , Guillaume Goldzak , Geraldine Paraclet , Thomas Grellety
{"title":"Long-term remission after multimodal therapy in metastatic small cell carcinoma of the ovary, hypercalcemic type: A case report","authors":"Elora Castanet ,&nbsp;Guillaume Goldzak ,&nbsp;Geraldine Paraclet ,&nbsp;Thomas Grellety","doi":"10.1016/j.gore.2025.102020","DOIUrl":"10.1016/j.gore.2025.102020","url":null,"abstract":"<div><h3>Background</h3><div>Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is an extremely rare and aggressive ovarian malignancy that predominantly affects young women. Prognosis is stage-dependent, with a 5-year overall survival (OS) of approximately 20% in advanced stages (II–IV). Treatment typically involves a multimodal approach.</div><div>Case Presentation.</div><div>We present the case of a 24-year-old woman diagnosed with stage IV SCCOHT presenting multiple pulmonary nodules and enlarged retroperitoneal lymph nodes. Following standard treatment protocols, including surgery, chemotherapy and high-dose chemotherapy with autologous stem cell rescue, she achieved a complete response and has remained in remission for over five years despite initial pulmonary metastases. Given the rarity of SCCOHT, management was guided by recommendations and through the expertise of a national reference center.</div></div><div><h3>Conclusion</h3><div>This case highlights that, while durable remission is possible, intensive multimodal therapy is required, and SCCOHT survivors face significant long-term challenges. A comprehensive, multidisciplinary survivorship approach is essential to optimize long-term outcomes and quality of life, in accordance with current guidelines.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102020"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abdominal wall blocks in robotic hysterectomy for endometrial cancer are associated with a modest reduction in the frequency of patients receiving post-operative intravenous opioids 子宫内膜癌机器人子宫切除术中腹壁阻滞与术后静脉注射阿片类药物的患者频率适度降低相关
IF 1.3
Gynecologic Oncology Reports Pub Date : 2026-02-01 Epub Date: 2025-12-06 DOI: 10.1016/j.gore.2025.101995
Ioana Bondre , H. Meryem Soylu , Francesca Corbetta , Breana Hill , Elise Wilson , Rodney Gabriel , Ramez Eskander , Michael McHale , Cheryl Saenz , Pratibha Binder , Steven Plaxe
{"title":"Abdominal wall blocks in robotic hysterectomy for endometrial cancer are associated with a modest reduction in the frequency of patients receiving post-operative intravenous opioids","authors":"Ioana Bondre ,&nbsp;H. Meryem Soylu ,&nbsp;Francesca Corbetta ,&nbsp;Breana Hill ,&nbsp;Elise Wilson ,&nbsp;Rodney Gabriel ,&nbsp;Ramez Eskander ,&nbsp;Michael McHale ,&nbsp;Cheryl Saenz ,&nbsp;Pratibha Binder ,&nbsp;Steven Plaxe","doi":"10.1016/j.gore.2025.101995","DOIUrl":"10.1016/j.gore.2025.101995","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the association of abdominal wall blocks at the time of robotic hysterectomy performed for endometrial cancer (EC) with in-hospital post-operative opioids.</div></div><div><h3>Methods</h3><div>We performed a retrospective cohort study of patients in the Vizient database<!--> <!-->who had robotic hysterectomy for EC between January 2019 and December 2022. The exposure was any<!--> <!-->block coded separate from the surgery, and the primary outcomes were any IV/oral opioid. Fentanyl was excluded due to frequent intra-op<!--> <!-->use. Length of stay (LOS) and<!--> <!-->direct cost<!--> <!-->were compared. The association between block and opioid use<!--> <!-->was assessed via risk ratio. The quantity of each opioid was expressed in standard resource units (SRU) – a metric<!--> <!-->used to standardize the consumption of medications across facilities.</div></div><div><h3>Results</h3><div>Three hundred and twenty of the 9062 patients (3.5 %) had a block and 8,742 (96.5 %) did not. Blocks were performed at 66 (20.4 %) hospitals.<!--> <!-->184 patients (57.5 %) in the block group received an IV opioid vs 5,890 (67.4 %) of the<!--> <!-->patients without a block (RR 0.85, 95 % CI 0.77–0.94, p &lt; 0.001). Patients who received blocks were less likely to receive IV (52.5 % vs 64.8 %, RR 0.81, 95 % CI 0.73–0.89, p &lt; 0.001)<!--> <!-->and oral hydromorphone (6.9 % vs 3.9 %, RR 2.53, 95 % CI 1.68–3.81, p &lt; 0.001)<!--> <!-->and more likely to receive oral hydrocodone/acetaminophen (11.3 % vs 0.88 %, RR 12.77, 95 % CI 8.73–18.67, p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Blocks are infrequently performed and<!--> <!-->are associated with a modest reduction in the number of patients receiving post-op IV opioids.<!--> <!-->We found no difference<!--> <!-->in<!--> <!-->LOS or cost. Limitations include lack of detail regarding type of block, anesthetic, and phase of care.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 101995"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145697958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oncologically safe minimally invasive management of a 25 cm cystic abdominopelvic mass using contained, controlled drainage and removal 肿瘤安全微创治疗25厘米囊性腹腔肿块,采用封闭、控制引流和切除
IF 1.3
Gynecologic Oncology Reports Pub Date : 2026-02-01 Epub Date: 2026-01-07 DOI: 10.1016/j.gore.2025.102014
Yasmin Abozenah , Michelle Greenman , Ashley Goreshnik , Gary Altwerger
{"title":"Oncologically safe minimally invasive management of a 25 cm cystic abdominopelvic mass using contained, controlled drainage and removal","authors":"Yasmin Abozenah ,&nbsp;Michelle Greenman ,&nbsp;Ashley Goreshnik ,&nbsp;Gary Altwerger","doi":"10.1016/j.gore.2025.102014","DOIUrl":"10.1016/j.gore.2025.102014","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102014"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145972992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systemic inflammation indices and serum squamous cell carcinoma (SCC) antigen: an exploratory analysis on prognosis of patients with vulvar squamous cell carcinoma 全身炎症指标及血清鳞状细胞癌抗原对外阴鳞状细胞癌患者预后的探索性分析
IF 1.3
Gynecologic Oncology Reports Pub Date : 2026-02-01 Epub Date: 2025-12-19 DOI: 10.1016/j.gore.2025.102012
Luigi Della Corte , Mario Palumbo , Dominga Boccia , Antonisia Pollio , Daniela Terracciano , Giuseppe Bifulco
{"title":"Systemic inflammation indices and serum squamous cell carcinoma (SCC) antigen: an exploratory analysis on prognosis of patients with vulvar squamous cell carcinoma","authors":"Luigi Della Corte ,&nbsp;Mario Palumbo ,&nbsp;Dominga Boccia ,&nbsp;Antonisia Pollio ,&nbsp;Daniela Terracciano ,&nbsp;Giuseppe Bifulco","doi":"10.1016/j.gore.2025.102012","DOIUrl":"10.1016/j.gore.2025.102012","url":null,"abstract":"<div><h3>Objective</h3><div>To explore the relationship between hematologic inflammatory indices, serum squamous cell carcinoma antigen (SCC-Ag), and clinicopathological features in vulvar squamous cell carcinoma (VSCC).</div></div><div><h3>Methods</h3><div>Twenty-seven women with primary VSCC were prospectively analyzed. Peripheral leukocyte subsets and derived ratios, including neutrophil-to-lymphocyte (NLR), lymphocyte-to-monocyte (LMR), and eosinophil-to-lymphocyte ratio (ELR), were assessed preoperatively. SCC-Ag was measured in 16 patients and analyzed using a 1.9  ng/mL cut-off. Associations with tumor grade, recurrence, and mortality were investigated through non-parametric tests and ROC analysis.</div></div><div><h3>Results</h3><div>Patients with SCC-Ag ≥ 1.9  ng/mL showed significantly lower lymphocyte counts (1.66 vs. 2.41 × 10<sup>3</sup>/µL, p = 0.021) and higher tumor grade (median G3 vs. G2, p = 0.035), along with trends toward higher NLR and lower LMR. No significant differences emerged for other leukocyte subsets or ratios. Exploratory analyses suggested that both SCC-Ag and NLR were associated with recurrence and mortality at 12 months. Their combination improved prognostic discrimination, suggesting a potential role for integrated inflammatory markers in risk stratification.</div></div><div><h3>Conclusions</h3><div>Elevated SCC-Ag levels in VSCC are associated with lymphopenia and poor tumor differentiation, reflecting an unfavorable systemic immune profile. The combination of SCC-Ag and inflammatory indices, particularly NLR, may offer a simple and cost-effective tool for postoperative prognostic assessment and surveillance planning.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102012"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dapsone-induced methemoglobinemia in gynecologic cancer patients treated with immune checkpoint Inhibitors: a case series 用免疫检查点抑制剂治疗的妇科癌症患者中氨苯砜诱导的高铁血红蛋白血症:一个病例系列
IF 1.3
Gynecologic Oncology Reports Pub Date : 2026-02-01 Epub Date: 2026-01-31 DOI: 10.1016/j.gore.2026.102039
Julia C. Sakach , Sydney Anderson , Cassidy Abdeen , Danielle Glassman , Casey M. Cosgrove , Robert T. Neff , Laura J. Chambers
{"title":"Dapsone-induced methemoglobinemia in gynecologic cancer patients treated with immune checkpoint Inhibitors: a case series","authors":"Julia C. Sakach ,&nbsp;Sydney Anderson ,&nbsp;Cassidy Abdeen ,&nbsp;Danielle Glassman ,&nbsp;Casey M. Cosgrove ,&nbsp;Robert T. Neff ,&nbsp;Laura J. Chambers","doi":"10.1016/j.gore.2026.102039","DOIUrl":"10.1016/j.gore.2026.102039","url":null,"abstract":"<div><h3>Background</h3><div>Immune checkpoint inhibitors (ICI) activate antitumor immunity which can lead to the development of immune-related adverse events (irAE) that often require management with high-dose corticosteroids. The dosing and duration of corticosteroid therapy necessitates antibiotic prophylaxis against Pneumocystis jirovecii pneumonia (PJP). In patients that cannot use first-line trimethoprim–sulfamethoxazole, dapsone is a common alternative. A rare, serious complication of dapsone use is methemoglobinemia. Here, we present a case series of 3 gynecologic oncology patients on PJP prophylaxis with dapsone for irAEs related to ICI therapy who developed acquired-methemoglobinemia.</div></div><div><h3>Methods</h3><div>This is a case series and review of literature. Patient consent was obtained prior to initiation of the series and submission to the journal.</div></div><div><h3>Objective</h3><div>This case series describes three gynecologic oncology patients on ICI therapy who, while receiving dapsone for PJP prophylaxis during corticosteroid treatment for irAEs, presented to care with hypoxia and nonspecific symptoms. The presence of persistent hypoxia despite oxygen supplementation increased clinical suspicion of a dyshemoglobinemia and co-oximetry confirmed methemoglobinemia. Dapsone, the offending agent, was discontinued and patients were supportively managed with one patient additionally receiving methylene blue. This series aims to highlight the diagnostic challenges, overlap with ICI pneumonitis, and key management considerations.</div></div><div><h3>Conclusions</h3><div>Dapsone-induced methemoglobinemia is an important diagnostic consideration in gynecologic oncology patients on ICIs, particularly when faced with refractory hypoxia despite appropriate management of presumed immune-related toxicity. Recognition of acquired methemoglobinemia’s characteristic laboratory features and timely cessation of dapsone are vital to ensuring accurate diagnosis and to optimizing patient outcomes.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102039"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146170248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书